Osilodrostat, sold under the brand name ISTURISA, is now available as an oral tablet for adults with Cushing’s disease — a significant shift for patients who previously had to rely on injectable treatments like pasireotide to manage excess cortisol production. Manufactured by Recordati and originally developed by Novartis, the drug first received FDA approval on March 6, 2020, for adults with Cushing’s disease who either cannot undergo pituitary surgery or for whom surgery failed to provide a cure. Then, in April 2025, the FDA expanded the label to cover endogenous hypercortisolemia in adults with Cushing’s syndrome more broadly, opening the door for a wider population of patients dealing with the damaging effects of chronic cortisol overload. For anyone caring for a loved one with dementia or cognitive decline, this matters more than you might expect.
Prolonged exposure to elevated cortisol is well established as a risk factor for hippocampal atrophy, memory impairment, and accelerated neurodegeneration. Cushing’s syndrome, left undertreated, can compound existing cognitive vulnerabilities or even mimic dementia symptoms outright. Having a pill-form treatment that patients can take twice daily at home — rather than scheduling injections at a clinic — removes a meaningful barrier to consistent cortisol management, particularly for older adults already navigating complex care routines. This article covers how the drug works, what the clinical data actually shows, what it costs, how it compares to alternatives, and what caregivers and patients should watch for.
Table of Contents
- What Is the Pill Form Drug for Cushing’s Disease and How Does It Work?
- What the Clinical Evidence Says About Osilodrostat’s Effectiveness
- Why Cortisol Control Matters for Brain Health and Dementia Risk
- Comparing Oral Treatment Options for Cushing’s Syndrome
- Side Effects, Risks, and What Caregivers Should Watch For
- The Cost Reality and Patient Assistance Programs
- What Comes Next for Cushing’s Treatment
- Conclusion
- Frequently Asked Questions
What Is the Pill Form Drug for Cushing’s Disease and How Does It Work?
ISTURISA (osilodrostat) comes in 1 mg and 5 mg oral tablets, taken twice daily — once in the morning and once in the evening. Its mechanism is straightforward compared to some older approaches: it inhibits 11β-hydroxylase, the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. Rather than blocking cortisol at the receptor level after it has already been produced, osilodrostat cuts off production at the source. Think of it as turning down the faucet rather than mopping the floor. This distinction matters clinically. The older oral option, Korlym (mifepristone), works by blocking the cortisol receptor — cortisol levels in the blood remain high, but the body’s tissues are shielded from its effects. That approach has its place, but it makes monitoring treatment response more difficult because standard cortisol lab tests will still come back elevated even when the drug is working.
With osilodrostat, cortisol levels themselves drop, giving clinicians a clearer laboratory signal of whether the treatment is doing its job. For caregivers tracking a loved one’s progress, that measurable feedback loop can be genuinely reassuring. One important caveat: osilodrostat is not a cure. It manages cortisol levels for as long as the patient takes it. If the underlying cause of Cushing’s — whether a pituitary adenoma, an adrenal tumor, or ectopic ACTH production — remains in place, stopping the drug means cortisol will climb again. Surgery, when feasible, remains the first-line treatment. ISTURISA fills a critical gap for patients who are not surgical candidates or who relapsed after an operation.
What the Clinical Evidence Says About Osilodrostat’s Effectiveness
The pivotal LINC 3 study provided the backbone of the initial FDA approval. After 24 weeks of treatment, approximately 50% of patients achieved cortisol levels within the normal range — a meaningful result for a condition where even partial cortisol reduction can ease symptoms like weight gain, muscle wasting, bone loss, and cognitive fog. However, it also means that roughly half of patients did not fully normalize on the drug, so expectations should be calibrated accordingly. Partial responders may still benefit, but additional interventions might be needed. A randomized withdrawal portion of the clinical program produced more striking numbers. Among patients who continued osilodrostat, 86.1% maintained a complete response, compared to only 29.4% of those switched to placebo.
That gap underscores both the drug’s real efficacy and the reality that Cushing’s symptoms will return without ongoing treatment. It is not a medication you taper off once you feel better. Real-world data from the LINC 6 study, also called ILLUSTRATE, paints a somewhat more optimistic picture than the controlled trials. At three months, urinary free cortisol normalized in 71.4% of patients, serum cortisol normalized in 69.2%, and late-night salivary cortisol — often the most sensitive marker — normalized in 50%. These numbers, drawn from clinical practice rather than a controlled setting, suggest the drug performs at least as well outside of trial conditions. Across Recordati’s entire LINC clinical development program, data from more than 350 patients supported the expanded FDA label.
Why Cortisol Control Matters for Brain Health and Dementia Risk
Chronic hypercortisolism does not just cause the visible hallmarks of Cushing’s — the moon face, the buffalo hump, the abdominal weight gain. It quietly damages the brain. The hippocampus, the region most critical for forming new memories, is densely packed with cortisol receptors, making it particularly vulnerable to prolonged exposure. Studies have shown that patients with untreated Cushing’s syndrome exhibit measurable hippocampal volume loss and perform worse on tests of memory, attention, and executive function compared to age-matched controls. For someone already living with mild cognitive impairment or early-stage dementia, an undiagnosed or undertreated cortisol disorder can accelerate decline in ways that get attributed to the dementia itself.
Clinicians sometimes miss the overlap. A patient whose cognitive symptoms worsen might get an Alzheimer’s medication adjustment when what they actually need is cortisol management. This is not common, but it is not rare either — Cushing’s syndrome affects an estimated 10 to 15 per million people annually, and subclinical hypercortisolism is thought to be significantly more prevalent. The practical takeaway for caregivers: if a loved one with cognitive decline also has unexplained weight changes, thin skin that bruises easily, new-onset diabetes, or persistent high blood pressure, it is worth asking their physician whether cortisol testing is appropriate. Effective cortisol normalization, whether through surgery or a drug like osilodrostat, has been associated with partial recovery of hippocampal volume and cognitive function in some patients — though recovery is neither guaranteed nor always complete.
Comparing Oral Treatment Options for Cushing’s Syndrome
Patients and caregivers now have two oral medications to discuss with their endocrinologist, and the differences between them are clinically meaningful. Osilodrostat (ISTURISA) reduces cortisol production directly by blocking the enzyme 11β-hydroxylase. Mifepristone (Korlym) blocks the glucocorticoid receptor, preventing cortisol from exerting its effects on tissues even though circulating cortisol levels remain elevated or may even increase. Both are taken as pills. Both avoid the burden of injections. The tradeoff comes down to monitoring and side effect profiles.
Because osilodrostat actually lowers measurable cortisol, physicians can track treatment response with standard lab work — urinary free cortisol, serum cortisol, salivary cortisol. With mifepristone, those labs become unreliable as markers of treatment success, and clinicians must rely more heavily on clinical signs — is the patient losing weight, is blood sugar improving, is blood pressure coming down. For an older adult with dementia who may have difficulty articulating how they feel, objective lab markers can be a significant advantage. On the other hand, mifepristone has a longer track record, having been available since 2012, and some patients respond well to it when other options have not worked. A third oral option, relacorilant from Corcept Therapeutics, was expected to join this market but was denied FDA approval on December 30, 2025, with the agency citing insufficient evidence of effectiveness. That rejection narrows the oral landscape and makes the choice between osilodrostat and mifepristone even more central to treatment planning. Patients who were waiting on relacorilant as a potential alternative now have a clearer, if more limited, set of options.
Side Effects, Risks, and What Caregivers Should Watch For
The most significant risk with osilodrostat is adrenal insufficiency — the drug can overshoot, suppressing cortisol production below the level the body needs to function. Symptoms of adrenal insufficiency include severe fatigue, dizziness, nausea, low blood pressure, and in serious cases, adrenal crisis, which is a medical emergency. Patients on ISTURISA need regular cortisol monitoring, especially during dose adjustments, and caregivers should know the warning signs. This is not a drug you simply fill and forget. Other common side effects reported in clinical trials include headache, vomiting, nausea, fatigue, and edema. For older adults already dealing with frailty or polypharmacy, these effects deserve honest discussion with the prescribing physician.
Nausea and vomiting in particular can interfere with nutrition and hydration — problems that compound quickly in someone with cognitive impairment who may not communicate discomfort effectively. Dose titration is typically gradual, starting low and adjusting based on cortisol levels and tolerability, but the twice-daily dosing schedule requires reliable medication management. There is also the issue of drug interactions. Osilodrostat is metabolized through the liver, and patients taking other medications — which describes virtually every older adult with Cushing’s syndrome — need their full medication list reviewed by a pharmacist or physician before starting treatment. QT prolongation, a heart rhythm concern, has been flagged in prescribing information, and an ECG may be required before and during treatment. None of these risks are disqualifying, but they demand the kind of attentive medical oversight that caregivers should actively advocate for.
The Cost Reality and Patient Assistance Programs
ISTURISA is expensive. At approximately $11,550 per month under group purchasing organization pricing — and roughly $12,128 per month for Medicare patients — it is priced in line with other rare disease therapies but far beyond what most families can absorb without insurance. For commercially insured patients, Recordati’s R.A.R.E.
Patient Support Program may reduce out-of-pocket costs to as low as $20 per month, which is a dramatic reduction but requires navigating the enrollment process and meeting eligibility criteria. Medicare patients, who make up a substantial portion of the Cushing’s population given the age demographics, face a more complicated picture. Medicare Part D coverage will apply, but even with the Inflation Reduction Act’s $2,000 annual out-of-pocket cap on prescription drugs taking effect, the monthly cost remains high enough that formulary placement, prior authorization requirements, and step therapy protocols can delay access. Caregivers should work with the prescribing physician’s office and a specialty pharmacy to begin the insurance authorization process early — well before the patient needs to start the medication.
What Comes Next for Cushing’s Treatment
The expanded FDA indication for osilodrostat in April 2025, covering the broader category of Cushing’s syndrome rather than just the pituitary-driven disease subtype, signals that regulators see the drug’s clinical value extending to patients with adrenal or ectopic causes of hypercortisolism. This is a meaningful expansion. Many patients with Cushing’s syndrome from non-pituitary sources previously had fewer medical options and were more likely to require surgical interventions that carry their own risks.
With the FDA’s rejection of relacorilant in late 2025, the competitive landscape has thinned rather than expanded. Future developments to watch include longer-term safety data on osilodrostat, ongoing research into whether early cortisol normalization can prevent or slow cognitive decline in patients with hypercortisolism, and whether combination approaches — pairing cortisol-lowering drugs with neuroprotective strategies — emerge from the research pipeline. For now, having an effective oral option that directly reduces cortisol production represents a genuine, if incremental, advance for patients and the people who care for them.
Conclusion
Osilodrostat, marketed as ISTURISA, fills a real gap in Cushing’s disease and syndrome management by offering an oral tablet that directly reduces cortisol production — eliminating the need for injections and providing measurable lab markers to track treatment success. Clinical data from the LINC trials demonstrates meaningful cortisol normalization in a substantial portion of patients, and the expanded FDA label as of April 2025 broadens access to those with Cushing’s syndrome beyond the pituitary subtype. For brain health specifically, the link between chronic cortisol excess and hippocampal damage makes effective cortisol management relevant to anyone concerned about cognitive preservation.
The practical reality involves navigating significant costs, monitoring for adrenal insufficiency and other side effects, managing drug interactions, and maintaining a twice-daily dosing schedule that demands reliable medication oversight. None of these challenges are insurmountable, but they require active engagement from patients, caregivers, and clinical teams alike. If Cushing’s syndrome is part of your loved one’s medical picture, the availability of this oral treatment is a conversation worth having with their endocrinologist sooner rather than later.
Frequently Asked Questions
Is osilodrostat a cure for Cushing’s disease?
No. Osilodrostat manages cortisol levels by blocking the enzyme responsible for cortisol production, but it does not address the underlying cause such as a pituitary tumor. Surgery remains the first-line curative treatment when feasible. If osilodrostat is stopped, cortisol levels will rise again.
How does osilodrostat differ from mifepristone (Korlym)?
Osilodrostat reduces cortisol production at the adrenal gland level by inhibiting 11β-hydroxylase. Mifepristone blocks the cortisol receptor, meaning cortisol levels remain high but the body’s response to cortisol is blunted. Osilodrostat allows standard lab tests to track treatment response, while mifepristone requires more reliance on clinical signs.
What happened with the competing drug relacorilant?
The FDA denied approval of relacorilant, developed by Corcept Therapeutics, on December 30, 2025, citing insufficient evidence of effectiveness. This leaves osilodrostat and mifepristone as the primary oral options for Cushing’s syndrome.
Can high cortisol from Cushing’s syndrome worsen dementia or cognitive decline?
Yes. Chronic cortisol excess is associated with hippocampal atrophy, memory impairment, and accelerated neurodegeneration. Normalizing cortisol levels has been linked to partial recovery of brain volume and cognitive function in some patients, though results vary.
How much does ISTURISA cost without insurance?
Approximately $11,550 per month at group purchasing organization pricing. Commercially insured patients may qualify for Recordati’s R.A.R.E. Patient Support Program, which can reduce costs to as low as $20 per month. Medicare patients face coverage through Part D with associated prior authorization requirements.
What are the most serious side effects to watch for?
Adrenal insufficiency is the most significant risk, where cortisol drops too low. Symptoms include severe fatigue, dizziness, nausea, and low blood pressure. Other common side effects include headache, vomiting, fatigue, and edema. Regular cortisol monitoring is essential, especially during dose adjustments.
